Edgewise Therapeutics, Inc. (EWTX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript
Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement
Edgewise Therapeutics remains a "Buy," driven by pipeline focus and a transformative $2.65B sale of its muscular dystrophy program to Servier. Company will use the $1.55B upfront cash to fully fund EDG-7500 development for oHCM/nHCM, targeting pivotal phase 3 initiation in Q4 2026. Topline 12-week Part D data from the phase 2 CIRRUS-HCM study for EDG-7500 is expected in Q2 2026, a key catalyst for advancing to phase 3.
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
EWTX surges 18% to a record high after striking a $2.65 billion neuromuscular business divestiture deal with Servier, sharpening focus on its cardiovascular pipeline.
Edgewise Therapeutics, Inc. (EWTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Edgewise Therapeutics, Inc. (EWTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Edgewise Therapeutics, Inc. (EWTX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Edgewise Therapeutics, Inc. (EWTX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy
Edgewise Therapeutics (EWTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect?
The mean of analysts' price targets for Edgewise Therapeutics (EWTX) points to a 174.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data
Edgewise Therapeutics stock plunges 48% in a week following safety concerns for its investigational hypertrophic cardiomyopathy treatment candidate, EDG-7500.
Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On
The global hypertrophic cardiomyopathy market is expected to reach $1.35 billion by 2031. Despite a temporary stock drop due to adverse events and a $200 million stock offering, the long-term outlook for Edgewise Therapeutics, Inc. remains positive with multiple catalysts rapidly approaching for EWTX stock. Key milestones include 12-week data from the CIRRUS-HCM study in 2H 2025 and a phase 3 study initiation in 1H 2026.
Edgewise Therapeutics: More Expensive Now, But Much More Derisked
Edgewise Therapeutics' stock surged after strong midstage data from its Becker Muscular Dystrophy program, with the lead molecule sevasemten showing promising results. The GRAND CANYON trial, targeting Becker Muscular Dystrophy, aims for regulatory approval with primary endpoint NSAA, following positive Phase 2 CANYON data. Financially, Edgewise has a market cap of $2.67bn and a cash runway of 8-9 quarters, supporting ongoing and future trials.
Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data
Company achieved positive phase 2 CANYON study results for sevasemten in Becker Muscular Dystrophy, boosting long-term investment potential. Key catalysts include FDA and EMA meetings, GRAND CANYON study recruitment completion, and phase 2 CANYON data publication, all expected to likely enhance shareholder value. The pipeline extends beyond BMD, with sevasemten in phase 2 trials for Duchenne Muscular Dystrophy and EDG-7500 targeting Hypertrophic Cardiomyopathy, offering multiple growth opportunities.
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study
Data from a mid-stage study show that treatment with Edgewise's experimental drug reduces levels of a biomarker related to skeletal muscle damage.
